ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma-MedSci.cn

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021; 19 (3): 13

科室
- - 订阅+
  - 更多科室
工具
服务